+971 56 274 1787WhatsApp
psychiatric-behavioral-health ConditionNeurological

Addiction & Substance Abuse

"Compulsive urge to use substances despite knowing the harm they cause"

15+
Days/Month
50-70%
Medication Overuse
2-3x
Stroke Risk
Reversible
With Treatment
Understanding Your Condition

What is Chronic Migraine?

Addiction/Substance Abuse is a chronic, relapsing brain disorder characterized by compulsive drug seeking and use despite harmful consequences. It involves dysregulation of the mesolimbic dopamine pathway, impaired prefrontal cortex function, altered reward circuitry, and persistent changes in neurotransmitter systems including dopamine, glutamate, and GABA. Common substances include alcohol, opioids, stimulants, benzodiazepines, cannabis, and nicotine.

Healthy Function

What your body should do

A healthy reward system involves the ventral tegmental area releasing dopamine into the nucleus accumbens in response to natural rewards (food, social connection, achievement). The prefrontal cortex exercises executive control over impulsive drives, allowing for decision-making, delay of gratification, and behavioral inhibition. The extended amygdala regulates stress responses and provides balance to the reward system. Healthy neurotransmitter function includes adequate dopamine for motivation and reward, GABA for calming effects, and glutamate for cognitive function, all working in concert to maintain behavioral balance.

When Things Go Wrong

Signs of chronification

  • Pain threshold lowers over time
  • More frequent attacks
  • Brain stays in alert mode
  • Medication stops working
Development Process

How This Develops

Understanding the biological mechanisms helps us target the root cause

Point 1

Understanding the mechanism helps us target the root cause rather than just treating symptoms.

Symptom Manifestations

Recognizing All Symptoms

Chronic migraine affects multiple systems. Understanding your symptoms helps us identify the underlying mechanisms.

Physical Symptoms

13 symptoms

  • Tolerance: needing more to achieve same effect
  • Withdrawal symptoms when stopping (tremors, sweating, nausea, vomiting)
  • Physical deterioration: weight changes, poor hygiene
  • Insomnia or hypersomnia
  • Chronic fatigue and low energy
  • Headaches and dizziness
  • Gastrointestinal problems (nausea, constipation, diarrhea)
  • Respiratory problems (if smoking substances)
  • Cardiovascular issues (palpitations, high blood pressure)
  • Neurological symptoms (numbness, tingling, seizures in withdrawal)
  • Signs of injection: needle marks, skin infections
  • Alcohol-specific: flushed face, slurred speech, unsteady gait
  • Opioid-specific: constricted pupils, drowsiness, itching

Cognitive Symptoms

10 symptoms

  • Preoccupation with obtaining and using substances
  • Cravings that feel overwhelming
  • Difficulty with decision-making and planning
  • Impaired judgment and risk-taking
  • Memory problems and blackouts
  • Difficulty concentrating
  • Denial about the extent of the problem
  • Rationalization and minimization of use
  • Obsessive thinking about next use
  • Difficulty learning from negative consequences

Emotional Symptoms

10 symptoms

  • Mood swings and emotional instability
  • Anxiety, especially during withdrawal
  • Depression, often co-occurring
  • Irritability and anger
  • Feelings of shame and guilt
  • Low self-esteem
  • Numbness or emotional blunting
  • Hopelessness and despair
  • Social isolation and relationship conflicts
  • Defensiveness when confronted about use

Metabolic Symptoms

9 symptoms

  • Weight loss or gain depending on substance
  • Nutritional deficiencies
  • Dehydration
  • Electrolyte imbalances
  • Blood sugar dysregulation
  • Liver dysfunction
  • Kidney stress
  • Compromised immune function
  • Hormonal imbalances (testosterone, cortisol)
Commonly Associated

Conditions That Occur Together

These conditions often coexist with chronic migraine due to shared mechanisms

Related Condition

Depression

Bidirectional relationship; 30-50% of substance use disorder patients have comorbid depression; self-medication hypothesis; shared neurobiology involving dopamine and serotonin systems

Related Condition

Anxiety Disorders

High comorbidity rates (40-60%); alcohol often used for self-medication; benzodiazepine withdrawal mimics anxiety; shared genetic and environmental risk factors

Related Condition

Post-Traumatic Stress Disorder (PTSD)

Trauma often precedes and maintains addiction; 50% of PTSD patients meet criteria for substance use disorder; self-medication to numb traumatic memories

Related Condition

Chronic Pain

Opioid prescriptions for pain led to epidemic; chronic pain patients develop dependence; bidirectional relationship between pain and substance use

Related Condition

Sleep Disorders

Alcohol disrupts sleep architecture; withdrawal causes insomnia; sleep disturbance increases relapse risk; common in early recovery

Related Condition

Attention Deficit Hyperactivity Disorder (ADHD)

ADHD increases vulnerability to substance use 2-3x; stimulant medications can be misused; dopamine dysregulation common to both conditions

Related Condition

Gastrointestinal Disorders

Alcohol causes gastritis, ulcers, pancreatitis; opioids cause constipation; gut-brain axis involvement in cravings

Related Condition

Liver Disease

Alcoholic hepatitis, cirrhosis; also affects metabolism of substances and medications; contributes to cognitive impairment

Related Condition

Cardiovascular Disease

Stimulant use causes hypertension, arrhythmias; alcohol can cause cardiomyopathy; IV use risk of endocarditis

Differential Diagnoses

Conditions to Rule Out

These conditions can present similarly but have distinct features

Condition

Substance Use Disorder (SUD)

Overlapping

Impaired control, social impairment, risky use, tolerance, withdrawal

Key Difference

DSM-5 criteria require 2+ of 11 criteria within 12-month period; severity graded as mild (2-3), moderate (4-5), or severe (6+)

Condition

Dependence (Physical)

Overlapping

Tolerance, withdrawal

Key Difference

Physical dependence can occur without addiction (e.g., certain medications); characterized by physiological adaptation, not necessarily compulsive use

Condition

Abuse (Substance Abuse)

Overlapping

Risky use, failure to fulfill roles

Key Difference

Pre-DSM-5 term; did not include tolerance and withdrawal; replaced by SUD which captures more nuanced presentation

Condition

Addiction (Behavioral)

Overlapping

Compulsive behaviors, loss of control

Key Difference

Term often used interchangeably with SUD; behavioral addictions (gambling, internet) lack substance involvement but similar neurobiology

Condition

Relapse

Overlapping

Return to use after abstinence

Key Difference

Part of chronic disease model; not a treatment failure but a temporary setback requiring recommencement of treatment

Condition

Tolerance

Overlapping

Need for more substance

Key Difference

Physiological adaptation; can develop without dependence or addiction; common with many medications

Condition

Withdrawal

Overlapping

Physical symptoms upon cessation

Key Difference

Physiological response to cessation; varies by substance; can be medically managed; does not equal addiction

Condition

Pseudo-addiction

Overlapping

Drug-seeking behavior

Key Difference

Behavior driven by uncontrolled pain, not euphoria; resolves with adequate pain management

Root Causes

What's Driving Your Migraines

Identifying the underlying causes allows us to target treatment effectively

1

Genetic Predisposition

40-60% - Family history increases risk 2-4x; specific genes affect dopamine signaling (DRD2, DRD4), alcohol metabolism (ADH1B, ALDH2), and reward sensitivity

Family history assessment; genetic testing for risk variants; adoption studies confirm genetic contribution

2

Early Exposure

30% - Adolescent brain particularly vulnerable; early use increases addiction risk 2-3x; prefrontal development disrupted

Age of first use; developmental history; assess brain development impact

3

Chronic Stress

35% - Stress increases substance use motivation; elevates CRF and drives negative reinforcement cycle

Stress history; ACE score; cortisol testing; life events assessment

4

Trauma

40% - Adverse childhood experiences strongly predict addiction; trauma drives self-medication

Trauma history; ACE questionnaire; PTSD screening

5

Mental Health Conditions

50% - Comorbid psychiatric disorders increase addiction risk; self-medication hypothesis

Comprehensive psychiatric evaluation; assess for depression, anxiety, ADHD, PTSD

6

Social Environment

30% - Peer influence; availability; social norms around use; family patterns

Social history; peer network assessment; family history of use

7

Reward Sensitivity

25% - Variable dopamine system sensitivity; high reward sensitivity increases vulnerability

Behavioral assessments; personal history of reward-seeking behaviors

8

Impaired Executive Function

30% - Prefrontal cortex deficits affect impulse control, decision-making

Neuropsychological testing; assess for ADHD; decision-making assessments

9

Chronic Pain

20% - Pain-driven opioid use; pain patients vulnerable to dependence

Pain history; opioid prescription history; alternative pain management assessment

Lab Assessment

Key Laboratory Markers

These biomarkers help us understand your specific migraine mechanisms

Test
Normal Range
Optimal Range
Clinical Significance
GGT (Gamma-Glutamyl Transferase)
Normal:0-55 U/L U/L
Optimal:0-30 U/L U/L
Liver enzyme elevated with chronic alcohol use; marker of heavy drinking
AST/ALT Ratio
Normal:0.5-1.5 ratio
Optimal:<1.0 ratio
Ratio >2 suggests alcoholic liver disease; AST typically elevated 2-6x normal in alcohol abuse
Mean Corpuscular Volume (MCV)
Normal:80-100 fL fL
Optimal:85-95 fL fL
Elevated MCV suggests chronic alcohol abuse; macrocytosis from folate deficiency
Carbohydrate-Deficient Transferrin (CDT)
Normal:<1.7% %
Optimal:<1.2% %
Specific marker for chronic heavy alcohol consumption; remains elevated 2-4 weeks after cessation
Ethyl Glucuronide (EtG)
Normal:Negative ng/mL
Optimal:Negative ng/mL
Direct metabolite of ethanol; detects recent alcohol use within 72 hours
Phosphatidylethanol (PEth)
Normal:<20 ng/mL ng/mL
Optimal:0 ng/mL ng/mL
Specific alcohol biomarker; elevated levels indicate chronic heavy drinking for 2-4 weeks
Urine Drug Screen
Normal:Negative qualitative
Optimal:Negative qualitative
Blood Alcohol Level
Normal:0% %
Optimal:0% %
Current intoxication level; legal limit typically 0.08% in most jurisdictions
HDL Cholesterol
Normal:40-60 mg/dL mg/dL
Optimal:50-70 mg/dL mg/dL
Moderate alcohol may raise HDL; very low levels may indicate nutritional deficiency
Folate
Normal:3-20 ng/mL ng/mL
Optimal:10-20 ng/mL ng/mL
Frequent deficiency in alcohol use disorder; contributes to macrocytosis and neurological symptoms
Magnesium
Normal:1.5-2.5 mg/dL mg/dL
Optimal:2.0-2.3 mg/dL mg/dL
Frequently depleted in alcohol use; deficiency contributes to withdrawal symptoms
Vitamin B12
Normal:200-900 pg/mL pg/mL
Optimal:500-800 pg/mL pg/mL
Often deficient in alcohol abuse; neurological function requires adequate levels
TSH
Normal:0.4-4.0 mIU/L mIU/L
Optimal:1.0-2.0 mIU/L mIU/L
Thyroid dysfunction common in addiction; hyper/hypothyroidism can mimic anxiety
Cortisol (AM)
Normal:5-25 mcg/dL mcg/dL
Optimal:8-14 mcg/dL mcg/dL
HPA axis dysregulation common; chronic stress and withdrawal affect levels
HbA1c
Normal:<5.7% %
Optimal:<5.5% %
Alcohol can affect blood sugar; some substances cause metabolic changes
HIV/Hepatitis Panel
Normal:Negative qualitative
Optimal:Negative qualitative
IV drug use increases transmission risk; routine screening recommended
Cost of Waiting

What Happens If Left Untreated

Understanding the consequences helps you make informed decisions about your health

Physical Health Deterioration

Months to years

Organ damage (liver, heart, brain); increased infection risk; neurological damage; cancer risk; premature death (average lifespan reduction 10-20 years)

Mental Health worsening

Immediate and progressive

Comorbid depression and anxiety worsen; increased suicide risk (10-20x higher); cognitive decline; emotional numbing

Relationships and Family Destruction

Progressive

Broken marriages; estrangement from children; lost friendships; family trauma passed to next generation

Occupational and Financial Collapse

Often within months

Job loss; bankruptcy; legal problems; homelessness; inability to maintain basic responsibilities

Legal Consequences

Variable

DUI arrests; drug possession charges; incarceration; criminal record affecting employment

Overdose and Death

Unpredictable

Opioid overdoses killed 80,000+ in US in 2021; Fentanyl contamination increasingly common; risk highest during relapse after tolerance reduction

Secondary Health Conditions

Years

HIV/Hepatitis from IV use; TB; pneumonia; cardiovascular disease; cancers linked to substance use

Quality of Life Annihilation

Immediate and progressive

Complete loss of meaningful life; isolation; shame; hopelessness; existential suffering

Time Matters

Don't wait for symptoms to worsen. Early intervention leads to better outcomes.

Diagnostic Approach

How is Chronic Migraine Diagnosed?

Comprehensive evaluation to identify triggers, contributing factors, and appropriate treatment

Comprehensive Addiction Assessment

Purpose:

Establish diagnosis and severity

DSM-5 criteria fulfillment; substance use history; consequences; readiness to change

Urine Drug Screen

Purpose:

Detect recent substance use

Opioids, amphetamines, cocaine, benzodiazepines, cannabis, barbiturates, metabolites

Blood Alcohol Level / Breathalyzer

Purpose:

Assess current intoxication

Blood alcohol concentration; recent use

Liver Function Tests

Purpose:

Assess alcohol impact on liver

GGT, AST, ALT, bilirubin; markers of alcoholic hepatitis, cirrhosis

Complete Blood Count

Purpose:

Assess overall health

MCV (macrocytosis), anemia, infection, immune function

Comprehensive Metabolic Panel

Purpose:

Assess organ function and electrolytes

Kidney function, electrolytes, blood sugar, liver function

Lipid Panel

Purpose:

Assess cardiovascular risk

Cholesterol, triglycerides; alcohol affects lipid metabolism

Infectious Disease Screening

Purpose:

Screen for bloodborne pathogens

HIV, Hepatitis B and C

Nutritional Assessment

Purpose:

Identify deficiencies

Vitamin B12, folate, magnesium, iron studies

Cardiac Biomarkers

Purpose:

Assess cardiovascular impact

For stimulant and alcohol use; troponin, ECG if indicated

Psychiatric Evaluation

Purpose:

Assess co-occurring disorders

Depression, anxiety, PTSD, ADHD screening; severity ratings

Neuropsychological Testing

Purpose:

Assess cognitive function

Executive function, memory, attention; frontal lobe assessment

Treatment Protocol

Our Integrative Approach

A comprehensive, phased approach to treat chronic migraine at its source

1
Phase 1

Comprehensive evaluation and medical stabilization

Comprehensive evaluation and medical stabilization

Complete addiction assessment using DSM-5 criteria,Medical evaluation and laboratory testing,Psychiatric evaluation for co-occurring disorders,Safe detoxification if medically indicated,Medication-assisted treatment initiation if appropriate,Motivational interviewing to enhance readiness,Establish therapeutic alliance,Assess social support and resources

2
Phase 2

Medical stabilization and withdrawal management

Medical stabilization and withdrawal management

Click to expand

3
Phase 3

Address underlying issues and build recovery skills

Address underlying issues and build recovery skills

Click to expand

4
Phase 4

Consolidate gains and prevent relapse

Consolidate gains and prevent relapse

Click to expand

5
Phase 5

Maintain sobriety and optimize quality of life

Maintain sobriety and optimize quality of life

Click to expand

6
Phase 6

Prevent relapse and thrive

Prevent relapse and thrive

Click to expand

Diet & Lifestyle

Supporting Your Treatment

Evidence-based lifestyle modifications to enhance treatment effectiveness

Success Metrics

What Success Looks Like

Complete abstinence from all substances of choice

No cravings or minimal manageable cravings

Restored physical health (normal labs, improved functioning)

Stable mood without substance-related mood disruption

Improved relationships and social functioning

Returned occupational/educational functioning

Legal issues resolved

Financial stability restored

Quality of life measures improved

Sustained engagement in recovery activities

Ability to handle stressors without substance use

Meaningful life goals being pursued

Common Questions

Frequently Asked Questions

Expertise Behind This Guide

Evidence-Based Information

Dr. Hafeel Sevdeer - DHA Licensed Integrative and Functional Medicine Physician with specialized training in addiction medicine, co-occurring disorders, and the neurobiology of recovery. Expert in treating substance use disorders using comprehensive functional medicine approaches combined with evidence-based behavioral therapies and medication-assisted treatment.

References

  1. 1. Volkow ND, Koob GF, McLellan AT. Neurobiologic advances from the brain disease model of addiction. N Engl J Med. 2016.
  2. 2. Koob GF, Volkow ND. Neurocircuitry of addiction. Neuropsychopharmacology. 2016.
  3. 3. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 5th Ed. DSM-5. 2013.
  4. 4. National Institute on Drug Abuse. Principles of Drug Addiction Treatment: A Research-Based Guide. NIH Publication No. 19-DA-5601. 2019.
  5. 5. Substance Abuse and Mental Health Services Administration. Treatment Improvement Protocol (TIP) Series. HHS Publication No. (SMA) 19-4523.
  6. 6. Kleber HD, Weiss RD, Anton RF Jr, et al. Practice guideline for the treatment of patients with substance use disorders. Am J Psychiatry. 2006.
  7. 7. Miller WR, Rollnick S. Motivational Interviewing: Helping People Change. 3rd ed. Guilford Press. 2012.
  8. 8. Koob GF. The dark side of emotion: The addiction perspective. Eur J Pharmacol. 2015.
  9. 9. Volkow ND, Wang GJ, Fowler JS, et al. Addiction: beyond dopamine reward circuitry. Proc Natl Acad Sci U S A. 2001.
  10. 10. Weiss RD, Griffin ML, Greenfield SF, et al. Group therapy for patients with substance use disorders. Focus. 2019.
  11. 11. Stahl SM. Essential Psychopharmacology: The Prescriber's Guide. Cambridge University Press. 2021.
  12. 12. World Health Organization. Atlas on Substance Use Disorders. Geneva: WHO. 2010.

Ready to Find Relief from Chronic Migraines?

Our integrative approach has helped hundreds of patients find lasting relief from chronic migraines. Schedule your comprehensive assessment today.

500+ Patients Treated
15+ Years Experience
Integrative Approach